SNUH-CD19-CAR-T

SNUH-CD19-CAR-T is an autologous chimeric antigen receptor T cell (CAR-T) therapy developed and manufactured by Seoul National University Hospital. It is produced from a patient’s own T cells, which are collected, genetically modified ex vivo to express a CAR targeting the B-lymphocyte antigen CD19, expanded in culture, and then reinfused into the patient. The engineered CAR enables the modified T cells to recognize and kill CD19-expressing malignant B cells with high specificity while minimizing damage to normal tissues. This therapy is primarily being investigated for relapsed or refractory (R/R) B-cell malignancies such as acute lymphoblastic leukemia (ALL) and other CD19-positive leukemias[1][2][3]. The product is manufactured on-site at Seoul National University Hospital using their Advanced Cell Gene Center GMP facilities[3].

Brand names

SNUH-CD19-CAR-TSNUH-CD-19-CAR-TSNUH-CD 19-CAR-T

Other names

CD19 Chimeric Antigen Receptor T Cells (Seoul National University Hospital)